

AMENDMENTS

Kindly make the following changes:

In the Claims:

Please cancel claims 3, 21 and 22 without prejudice to future prosecution thereof. Please amend claims 1-2, 6, 9, 10, 12-15, 17-20 and 23 without prejudice to future prosecution thereof.

1. (Amended) [Method] A method of increasing the therapeutic effect of a cancer therapy, comprising the steps of:

delivering a wild-type p53 gene [therapy-sensitizing gene activity] to a tumor cell which is deficient in its wild-type p53 gene [characterized by loss of said wild-type therapy-sensitizing gene activity], effecting the expression of said wild-type p53 gene in said tumor cell, and

subjecting said tumor cell to said cancer therapy.

2. (Amended) A method of increasing the therapeutic effect of a cancer therapy, comprising the steps of:

delivering a wild-type p53 protein to a tumor cell which is deficient in its wild-type p53 gene, and

subjecting said tumor cell to said cancer therapy.

Part of Claim 2

[The method of claim 1, wherein said delivering comprises introducing a portion of a therapy-sensitizing protein with said therapy-sensitization gene activity into the tumor cell.]

C 2

6. (Amended) The method of claim 1, wherein said cancer therapy is immunotherapy [biological therapy].

C 3

9. (Amended) The method of claim 1 wherein said tumor cell is selected from the group consisting of [carcinoma cell, sarcoma cell, central nervous system tumor cell, melanoma tumor cell,] leukemia cell, lymphoma tumor cell, [hematopoietic tumor cell,] ovarian carcinoma cell, osteogenic sarcoma cell, lung carcinoma cell, colorectal carcinoma cell, hepatocellular carcinoma cell, glioblastoma cell, prostate cancer cell, breast cancer cell, bladder cancer cell, kidney cancer cell, pancreatic cancer cell, gastric cancer cell, esophageal cancer cell, anal cancer cell, biliary cancer cell, and urogenital cancer cell[, and head and neck cancer cell].

10. (Amended) The method of claim [3] 1, wherein said [portion of a therapy-sensitizing gene or said portion of a cDNA] wild-type p53 gene is in a vector.

12. (Amended) The method of claim [3] 1, wherein said [portion of a therapy-sensitizing gene or said portion of a cDNA] wild-type p53 gene is coupled to a virus capsid or particle.

13. (Amended) The method of claim 12, wherein said [portion of a therapy-sensitizing gene or said portion of a cDNA] wild-type p53 gene is coupled to said capsid or particle through a polylysine bridge.

Cy
Cont
14. (Amended) The method of claim [3] 1, wherein said [portion of a therapy-sensitizing gene or said portion of a cDNA] wild-type p53 gene is encapsulated in a liposome.

15. (Amended) The method of claim [3] 1, wherein said [portion of a therapy-sensitizing gene or said portion of a cDNA] wild-type p53 gene is conjugated to a ligand.

17. (Amended) The method of claim [3] 1, wherein said [portion of a therapy-sensitizing gene or said portion of a cDNA] wild-type p53 gene is introduced to said tumor cell by direct injection.

CS
18. (Amended) The method of claim [3] 1, wherein said [portion of a therapy-sensitizing gene or said portion of a cDNA] wild-type p53 gene is introduced to said tumor cell by intra-arterial infusion.

19. (Amended) The method of claim [3] 1, wherein said [portion of a therapy-sensitizing gene or said portion of a cDNA] wild-type p53 gene is introduced to said tumor cell by intracavitary infusion.

20. (Amended) The method of claim [3] 1, wherein said [portion of a therapy-sensitizing gene or said portion of a cDNA] wild-type p53 gene is introduced to said tumor cell by intravenous infusion.